

Worthorne, Eric W.

---

From: Park, Sam <SPark@winston.com>  
Sent: Friday, September 29, 2017 12:19 PM  
Subject: Trials  
Parmelee, Steve; jmills@wsgr.com; mrosato@wsgr.com; jlove@gibsondunn.com; ahollis@kirkland.com; egoryunov@kirkland.com; greg.springsted@kirkland.com; RTrenchard@gibsondunn.com  
RE: IPR2017-01929 motion for joinder

Honors,

the lead counsel for Petitioners Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE (“Sun”) in IPR2017-01929.

I would like to inform the Board that counsel for joined petitioners Actavis Elizabeth LLC and Teva Pharmaceuticals USA, Inc. (collectively “Actavis”), independently, has informed Sun that Actavis does not oppose Sun’s motion to join IPR2017-00854. Sun agrees to the same conditions as set forth in paragraph 23 of IPR2017-00854.

Please let me know if you need any additional information. I have copied counsel for Patent Owner, Apotex, and Actavis to this correspondence.

Sincerely,  
Samuel S. Park (Reg. No. 59,656)  
Senior Counsel for Sun

**Samuel S. Park**

Senior Counsel  
Winston & Strawn LLP  
100 Wacker Drive  
Chicago, IL 60601-9703  
Tel: 312-558-7931  
Fax: 312-558-5700

[VCard](#) | [Email](#) | [winston.com](http://winston.com)

Winston & Strawn LLP is admitted to practice in Illinois, New York, U.S. Patent & Trademark Office

WINSTON  
STRAWN  
LLP

Consider the environment before printing this e-mail.

---

From: Trials [mailto:Trials@USPTO.GOV]  
Sent: Wednesday, September 27, 2017 12:38 PM  
To: Spark, Sam <SPark@winston.com>; jlove@gibsondunn.com  
Cc: Trials <Trials@USPTO.GOV>; Parmelee, Steve <sparmelee@wsgr.com>  
Subject: IPR2017-01929 motion for joinder

Dear Counsel,

On September 26, 2017, a representative of Petitioner Sun Pharma called to inquire about the status of their motion for joinder with IPR2017-00854, filed August 17, 2017. Paper 3. The time for Patent Owner to oppose the motion under 37 C.F.R. § 42.25(a)(1) has expired. Sun Pharma indicates that lead Petitioner of IPR2017-00854, Apotex, does not oppose the motion. *Id.* at 2; *see also, id.* at n.1 (indicating that joined Petitioner Argentum also does not oppose).

On September 9, 2017, we issued an Order further joining Actavis Elizabeth LLC and Teva Pharmaceuticals USA, Inc. (collectively “Actavis”) to this proceeding. *See* IPR2017-00854, Paper 23. To expedite our consideration of its motion, Sun Pharma should indicate if lead Petitioner Apotex speaks for Actavis, and if Actavis, independently, does not oppose the motion and agrees to the same conditions as set forth in Paper 23 of IPR2017-00854.

Sincerely,

Andrew Kellogg,  
Advisory Paralegal  
Patent Trial and Appeal Board  
USPTO  
[andrew.kellogg@uspto.gov](mailto:andrew.kellogg@uspto.gov)  
Phone: 571-272-5366

---

The contents of this message may be privileged and confidential. If this message has been received in error, please delete it without reading it. Your receipt of this message is not intended to waive any applicable attorney-client privilege. Please do not disseminate this message without the permission of the author. Any tax advice contained in this email was not intended to be used, and cannot be used, by you (or any other taxpayer) to avoid taxes under applicable tax laws and regulations.